Given that aberrant activation of FGFR1, VEGFR2, PDFGRα, Abl, and RET is related to other human malignancies, like lung and breast cancer, and medullary thyroid cancer, ponatinib-based targeted therapy may be beneficial for the aforementioned groups of cancer patients. The gene discussed is FGFR1; the disease is breast cancer.